Liabilities and Equity in USD of Amylyx Pharmaceuticals, Inc. from Q4 2021 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Amylyx Pharmaceuticals, Inc. quarterly Liabilities and Equity history and change rate from Q4 2021 to Q3 2025.
  • Amylyx Pharmaceuticals, Inc. Liabilities and Equity for the quarter ending September 30, 2025 was $363M, a 44.7% increase year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Change (%)

Amylyx Pharmaceuticals, Inc. Quarterly Liabilities and Equity (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $363M +$112M +44.7% Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $195M -$138M -41.4% Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $220M -$198M -47.4% Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $194M -$324M -62.6% Dec 31, 2024 10-Q 2025-11-06
Q3 2024 $251M -$216M -46.3% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $332M -$121M -26.8% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $417M +$9.5M +2.33% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $517M +$126M +32.2% Dec 31, 2023 10-K 2025-03-04
Q3 2023 $467M +$285M +157% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $454M +$228M +101% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $408M +$134M +48.7% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $391M +$286M +271% Dec 31, 2022 10-K 2024-02-22
Q3 2022 $181M Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $225M Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $274M Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $106M Dec 31, 2021 10-K 2023-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.